Semaglutide has long been revealed to result in medullary thyroid mobile carcinoma in rodents. Whilst its scientific relevance to humans is not known, the FDA advises to not administer this drug in Those people with a personal or relatives background of medullary thyroid carcinoma. Semaglutide also poses a hazard of pancreatitis and dehydration.Mec